Skip to search formSkip to main contentSkip to account menu

idarubicinol

Known as: 13-dihydroidarubicin, 4-demethoxy-14-hydroxydaunorubicin 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antineoplastic AgentsDaunorubicin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
Since the severe cardiotoxicity of anthracyclines has been attributed to the intramyocardial formation of C-13 alcohol… 
2001
2001
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance
The feasibility of adding both the multidrug resistance modulator cyclosporin (CsA) and granulocyte colony-stimulating factor (G… 
2000
2000
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia
Abstract Recent results show that the intracellular uptake pattern of idarubicin (IDA) in multidrug-resistant (MDR) cells is… 
Review
1997
Review
1997
Idarubicin: a brief overview on pharmacology and clinical use.
Idarubicin exhibits features rendering this drug unique among anthracyclines. The higher lipophilicity leads to faster… 
1997
1997
Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit
Abstract A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min… 
1996
1996
Cellular pharmacology of idarubicinol in multidrug‐resistant LoVo cell lines
Idarubicin (IDA) is a daunorubicin (DAU) analog that is being used to treat a variety of human malignancies. The major… 
Review
1995
Review
1995
Attenuated‐dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results
AML in the elderly is characterized by intrinsic biological features implying an enhanced chemoresistance. Intensive chemotherapy… 
1991
1991
DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.
This study assessed the ability of major metabolites of two types of anthracycline antibiotics, doxorubicin and idarubicin (4… 
1989
1989
Reversed-phase liquid chromatographic determination of idarubicin and its 13-hydroxy metabolite in human plasma.
1987
1987
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)